Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Read more about Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. Read more about Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.
The role of emerging therapy in the management of patients with diffuse low grade glioma. Read more about The role of emerging therapy in the management of patients with diffuse low grade glioma.
The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. Read more about The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Read more about Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma.
Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. Read more about Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials.
Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. Read more about Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study. Read more about Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. Read more about Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Familial gliomas: cases in two pairs of brothers. Read more about Familial gliomas: cases in two pairs of brothers.
